Highlights Bioxytran, Inc.

Equities

BIXT

US09075D1028

Market Closed - OTC Markets Other stock markets 20:44:45 10/05/2024 BST			5-day change	1st Jan Change
0.1106 ^USD	+0.55%		+9.40%	-26.27%

04-19	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-19	Bioxytran, Inc. Announces Board Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-19	CI
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
Bioxytran, Inc. Announces Preprint of Shingles Case Study Showing Clearance Using A Topical Galectin-3 Antagonist	03-06	CI
Bioxytran, Inc.'S Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for Covid-19	02-21	CI
Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
Bioxytran, Inc. Receives Clearance of its Investigational New Drug Application from U.S. Food and Drug Administration to Initiate Clinical Trials of ProLectin-M	24/08/23	CI
Bioxytran, Inc. Initiates A Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID 19 Patients	08/08/23	CI
Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/07/23	CI
Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Bioxytran, Inc. Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials	19/04/23	CI
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Bioxytran, Inc. Announces Positive Phase 2 Trial Results	29/03/23	CI
Bioxytran, Inc. Announces Vitro Testing At Foundation for Neglected Disease Research in Bangalore India	28/02/23	CI
Bioxytran, Inc. Receives Approval to Initiate Trials with Prolectin-I	06/02/23	CI
Bioxytran, Inc. Announces Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial	28/12/22	CI
Bioxytran Establishes Indian Subsidiary Pharmalectin India Private Limited in Preparation of Commercialization	14/12/22	CI
Bioxytran Receives Approval to Optimize Dosage in Covid-19 Patients	08/12/22	CI
BIOXYTRAN, INC. Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv Pre-print	16/11/22	CI
Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bioxytran, Inc.

Equities

BIXT

US09075D1028

Highlights

Filters